Amgen owns a vast portfolio of treatments in many areas. Rather than focusing on a particular field, the company has been known to release new drugs in the right places at the right time

In addition to actively developing drugs for chronic diseases such as the osteoporosis treatments 'Prolia (denosumab)’ and ‘Evenity (romosozumab),’ the osteoporosis complication prevention drug ‘Xgeva (denosumab),’ and the dyslipidemia treatment ‘Repatha (evolocumab),’ the company has also followed up with the recent trend and released oncology drugs such as the acute lymphoblastic leukemia drug ‘Blincyto (blinatumomab), multiple myeloma treatment 'Kyprolis (carfilzomib),' and the recent KRAS inhibitor ‘Luma